Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for arterial stiffness and metabolic outcomes in overweight adults with type 1 diabetes
ACTRN12623001277639Phase 2Active, not recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in diabetes mellitus type 1 (T1D), sponsored by Garvan Institute of Medical Research. Primary endpoint: Change in arterial stiffness. Started Mar 2024; status: active, not recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12623001277639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001277639.